vs
Side-by-side financial comparison of Orion Group Holdings Inc (ORN) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $216.3M, roughly 1.4× Orion Group Holdings Inc). Bio-Techne runs the higher net margin — 12.8% vs 2.2%, a 10.7% gap on every dollar of revenue. On growth, Orion Group Holdings Inc posted the faster year-over-year revenue change (14.6% vs -6.4%). Over the past eight quarters, Orion Group Holdings Inc's revenue compounded faster (6.1% CAGR vs 4.2%).
Orion Corporation, founded in 1917 and headquartered at Espoo, Finland, is a globally operating Finnish company which develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients for global markets. All of the company's manufacturing sites and the majority of its R&D units are in Finland.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
ORN vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $216.3M | $295.9M |
| Net Profit | $4.7M | $38.0M |
| Gross Margin | 12.0% | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 2.2% | 12.8% |
| Revenue YoY | 14.6% | -6.4% |
| Net Profit YoY | 435.7% | 68.3% |
| EPS (diluted) | $0.12 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $216.3M | — | ||
| Q4 25 | $233.2M | $295.9M | ||
| Q3 25 | $225.1M | — | ||
| Q2 25 | $205.3M | $317.0M | ||
| Q1 25 | $188.7M | $316.2M | ||
| Q4 24 | $216.9M | $297.0M | ||
| Q3 24 | $226.7M | $289.5M | ||
| Q2 24 | $192.2M | $306.1M |
| Q1 26 | $4.7M | — | ||
| Q4 25 | $-240.0K | $38.0M | ||
| Q3 25 | $3.3M | — | ||
| Q2 25 | $841.0K | $-17.7M | ||
| Q1 25 | $-1.4M | $22.6M | ||
| Q4 24 | $6.8M | $34.9M | ||
| Q3 24 | $4.3M | $33.6M | ||
| Q2 24 | $-6.6M | $40.6M |
| Q1 26 | 12.0% | — | ||
| Q4 25 | 11.6% | 64.6% | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 12.6% | 62.7% | ||
| Q1 25 | 12.2% | 67.9% | ||
| Q4 24 | 14.0% | 65.3% | ||
| Q3 24 | 11.9% | 63.2% | ||
| Q2 24 | 9.5% | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 2.2% | 18.4% | ||
| Q3 25 | 2.4% | — | ||
| Q2 25 | 1.7% | -7.5% | ||
| Q1 25 | 0.4% | 12.2% | ||
| Q4 24 | 4.4% | 16.0% | ||
| Q3 24 | 3.4% | 13.8% | ||
| Q2 24 | -1.4% | 15.0% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | -0.1% | 12.8% | ||
| Q3 25 | 1.5% | — | ||
| Q2 25 | 0.4% | -5.6% | ||
| Q1 25 | -0.7% | 7.1% | ||
| Q4 24 | 3.1% | 11.7% | ||
| Q3 24 | 1.9% | 11.6% | ||
| Q2 24 | -3.4% | 13.3% |
| Q1 26 | $0.12 | — | ||
| Q4 25 | $-0.00 | $0.24 | ||
| Q3 25 | $0.08 | — | ||
| Q2 25 | $0.02 | $-0.11 | ||
| Q1 25 | $-0.04 | $0.14 | ||
| Q4 24 | $0.22 | $0.22 | ||
| Q3 24 | $0.12 | $0.21 | ||
| Q2 24 | $-0.20 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.3M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $166.7M | $2.0B |
| Total Assets | $478.7M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $6.3M | — | ||
| Q4 25 | $1.6M | $172.9M | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | $1.7M | $162.2M | ||
| Q1 25 | $13.0M | $140.7M | ||
| Q4 24 | $28.3M | $177.5M | ||
| Q3 24 | $28.3M | $187.5M | ||
| Q2 24 | $4.8M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | $33.4M | $346.0M | ||
| Q1 25 | $23.3M | $330.0M | ||
| Q4 24 | $23.2M | $300.0M | ||
| Q3 24 | $28.0M | $300.0M | ||
| Q2 24 | $60.3M | $319.0M |
| Q1 26 | $166.7M | — | ||
| Q4 25 | $159.0M | $2.0B | ||
| Q3 25 | $157.9M | — | ||
| Q2 25 | $153.2M | $1.9B | ||
| Q1 25 | $150.8M | $2.0B | ||
| Q4 24 | $150.7M | $2.1B | ||
| Q3 24 | $142.4M | $2.1B | ||
| Q2 24 | $111.1M | $2.1B |
| Q1 26 | $478.7M | — | ||
| Q4 25 | $414.7M | $2.5B | ||
| Q3 25 | $422.4M | — | ||
| Q2 25 | $432.7M | $2.6B | ||
| Q1 25 | $416.3M | $2.6B | ||
| Q4 24 | $417.3M | $2.7B | ||
| Q3 24 | $430.3M | $2.7B | ||
| Q2 24 | $414.0M | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.22× | 0.18× | ||
| Q1 25 | 0.15× | 0.16× | ||
| Q4 24 | 0.15× | 0.14× | ||
| Q3 24 | 0.20× | 0.14× | ||
| Q2 24 | 0.54× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ORN
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
